2. Cautionary Language
The discussions at this meeting will include forward-
looking statements. Actual results could differ materially
from those projected in the forward-looking statements.
The factors that could cause actual results to differ are
discussed in our 2007 Annual Report on Form 10-K and
in our reports on Form 10-Q and 8-K. These reports are
available on our website at www.pfizer.com in the
“Investors – SEC Filings” section.
3. R&D Five Point Plan
Aggressively Deliver the Phase 2 and
Phase 3 Portfolio
Prioritize Our Portfolio to Deliver
the Most Value
Become a Top-Tier Biotherapeutics
Company
Dramatically Raise the Bar on
Productivity
Pursue the Best External Science
4. Rich In Substrate
85 distinct new molecular entities in our pipeline
26 biological programs in preclinical/clinical development
Pipeline breadth and depth in 10 therapeutic areas
Aggressive goal to rebuild our Phase 3 portfolio
Total of 15 - 20 Phase 3 starts 2008 - 2009
Phase 3 total programs grow to 24 - 28 by December 2009
15 - 20 regulatory submissions between 2010 - 2012
5. Pfizer R&D Pipeline
(as of February 28, 2008)
Over 300
Discovery
Projects
Phase 1
Phase 2 Approved
Phase 3
47 37 In Reg. Selzentry
16
Lyrica
2
Fibromyalgia
fesoterodine
(EU)
Accelerating Pipeline with Sharpened Focus on
Key Disease Areas
Strong flow of medicines expected to progress
from Phase 2 to Phase 3
7. Potential New Indications Expected
To Drive Value
Colorectal
es
nu
ve
Non Small Cell Lung
Re
Hepatocellular Carcinoma
Breast
Renal Cell Carcinoma & Gastrointestinal Stromal Tumor
Time
8. axitinib: Potential New Phase 3 Indications
Study 1016
ECOG PS 0/1
Ongoing Phase 3 trial in 1.0
axitinib+gemcitabine
pancreatic cancer (n=63)
Median: 7.2 mo
Anticipate at ASCO (95% CI: 6.0, 12.5)
0.8
Overall Survival Probability
gemcitabine (n=31)
Additional information on both
Median: 5.7 mo
pancreas and renal cell trials (95% CI: 4.1, 8.8)
0.6
Expect two new Phase 3
starts: 0.4
Renal cell cancer
Non-small cell lung cancer 0.2
Hazard ratio = 0.683
(95% CI: 0.42, 1.11)
0
0 2 4 6 8 10 12 14 16 18 20
Time (months)
Spano J et al., ECCO 2007
9. Projected 15–20 Phase 3 Starts 2008–2009
PF-3187207 PF-885706 – GERD PF-868554 PF-734200
– Glaucoma – HCV – Diabetes
PF-299804 – Cancer
CP-751871 PF-4194471 PF-4522625
PH-797804 – RA
– Lung Cancer – HIV – Seasonal Flu
NMEs IV sulopenem/Oral
PF-4383119 CP-690550 UK-453061
sulopenem pro-drug
– OA Pain – RA – HIV
– Bacterial Infections
PD-200390
– Insomnia
apixaban – VTE PF-4383119
treatment & ACS – Chronic Pain
axitinib – RCC & tremelimumab – CRC
New Lung
S,S-reboxetine – DPN
Indications
10. CP-751871 (IGF-1R Ab):
Proof Of Concept Established In 1st Line NSCLC
Carboplatin/Paclitaxel (SOC)
Study Treatment-naïve Stage IIIB/IV
NSCLC patients
Design Carboplatin/Paclitaxel + CP-751
60
Response Rate (%)
50
Highly specific fully
40 human antibody
30 Well tolerated – high
potential to combine
20
10 Broad proof-of-concept
development plan
0
underway
SOC SOC+CP-751871
(n=48)
(n=25)
All Adeno Nonadeno
Phase 2 Tumor Shrinkage Needs to Translate to
Phase 3 Survival Benefit for Registration
* carboplatin/paclitaxel
Karp et al ASCO 2007; Karp et al IASLC 2007
11. CP-690550:
JAK-3 Inhibitor
RA Phase 2a Response Rate
100
80
60
40
20
0
0 2 4 6
Weeks
Phase 2b dose ranging in rheumatoid
Placebo 5 mg 15 mg 30 mg
arthritis ongoing – anticipate
Kremer JM et al, ACR 2006 presentation at ACR 2008
Simultaneous Development Programs in Psoriasis, Asthma,
Transplant Rejection, Rheumatoid Arthritis and Crohn’s Disease
12. PF-4383119 (RN-624):
Nerve Growth Factor Inhibitor
Heavy
Projected 1st Biotherapeutic for Pain
Chain
Blocks Nerve Growth Factor (NGF)
Humanized monoclonal antibody
NGF
Efficacy demonstrated in Phase 2
osteoarthritis (OA) pain study
Favorable safety profile to date
>600 patients treated
Light
Chain
13. PF-4383119:
Osteoarthritis Knee Pain
Single IV Infusion: Mean Change from Baseline (mm) Over 8 Weeks
Panel 1 Panel 2
Baseline Pain = 43–46 mm Baseline Pain = 54–60 mm
n=12 n=6 n=6 n=6 n=26 n=27 n=26
0
-5
-10
-15
-20
-25
*
*
-30 *
*
-35
Placebo 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg
Encouraging Phase 1/2 Efficacy and Safety Data
* p<0.05 vs placebo
14. Projected 15–20 Submissions 2010–2012
axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes
– Malaria
S,S-reboxetine PD-200390 – Insomnia
– Fibromyalgia PF-299804 – Cancer
CP-751871
CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC
NMEs PD-332334 – GAD PF-4522625 – Seasonal Flu PF-4383119 – OA Pain
IV sulopenem / Oral PH-797804 – RA CP-690550 – RA
sulopenem pro-drug
PF-868554 – HCV
– Bacterial Infections
PF-4194471 – HIV
UK-453061 – HIV
axitinib – 1st Line S,S-reboxetine – DPN
nd
NSCLC & 2 Line RCC CP-690550 – Psoriasis
apixaban – VTE PF-4383119
New Treatment, AF & Acute – Chronic Pain
Coronary Syndrome
Indications
/
15. 86 Biotherapeutics In The Pipeline
Research Development Marketed
60 26 5
$1.4 B 2007
Diverse Portfolio Revenues
8 TAs
(dalteparin sodium injection)
(interferon beta-1a)
6 Modalities
53 MAbs
8 Vaccines
(pegvisomant for injection)
16. Delivery In Action
Selzentry/Celsentri Approved for Treatment Experienced HIV (US/EU)
Approved for Smoking Cessation, PAH (Japan)
Champix, Revatio
Zithromax SR Submitted for Bacterial Infections (Japan)
Submitted for Osteoporosis
Fablyn
Spiriva Respimat Submitted for COPD
Xalacom Submitted for Glaucoma (Japan)
PD-332334, S,S-reboxetine, Eraxis/Vfend, Geodon
Advanced to Phase 3
Adj Depression, axitinib & Neurontin Peds (Japan)
Potential New Oncology
Sutent, axitinib and tremelimumab
Indications
Business Development Encysive, CovX, Serenex, Coley
3 POCs, 11 FIPs, 17 FIHs
Early Portfolio
17. Strong And Growing Portfolio
New In-Line Established
(glipizide) Extended Release Tablets
Dynastat ®
IV/IM
(parecoxib sidico injectable)
